You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CIMETIDINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Cimetidine patents expire, and what generic alternatives are available?

Cimetidine is a drug marketed by Apotex, Chartwell Molecules, Chartwell Rx, Contract Pharmacal, Cycle, Hikma, Ivax Sub Teva Pharms, L Perrigo Co, Mylan, Novitium Pharma, Perrigo, Pliva, Sandoz, Teva, Upsher Smith Labs, Watson Labs Inc, Watson Labs Teva, Cosette, Endo Operations, Hospira, Luitpold, Teva Parenteral, Ani Pharms, Chartwell Molecular, G And W Labs Inc, Pai Holdings Pharm, Pharm Assoc, and Pharmobedient Cnsltg. and is included in forty-nine NDAs.

The generic ingredient in CIMETIDINE is cimetidine hydrochloride. There are twenty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cimetidine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cimetidine

A generic version of CIMETIDINE was approved as cimetidine hydrochloride by PAI HOLDINGS PHARM on October 28th, 1997.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CIMETIDINE?
  • What are the global sales for CIMETIDINE?
  • What is Average Wholesale Price for CIMETIDINE?
Drug patent expirations by year for CIMETIDINE
Drug Prices for CIMETIDINE

See drug prices for CIMETIDINE

Recent Clinical Trials for CIMETIDINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Phase 4
University of WashingtonPhase 4
Wollo UniversityPhase 4

See all CIMETIDINE clinical trials

Pharmacology for CIMETIDINE
Medical Subject Heading (MeSH) Categories for CIMETIDINE

US Patents and Regulatory Information for CIMETIDINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Luitpold CIMETIDINE HYDROCHLORIDE cimetidine hydrochloride INJECTABLE;INJECTION 074353-001 Dec 20, 1994 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Pliva CIMETIDINE cimetidine TABLET;ORAL 074566-001 Feb 27, 1997 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Mylan CIMETIDINE cimetidine TABLET;ORAL 074246-003 May 17, 1994 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Hospira CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER cimetidine hydrochloride INJECTABLE;INJECTION 074468-006 Dec 29, 1994 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Teva CIMETIDINE cimetidine TABLET;ORAL 074365-001 Feb 28, 1995 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Watson Labs Inc CIMETIDINE cimetidine TABLET;ORAL 074349-001 Aug 30, 1996 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Sandoz CIMETIDINE cimetidine TABLET;ORAL 074250-002 Jun 29, 1995 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

CIMETIDINE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Cimetidine

Introduction

Cimetidine, marketed under the brand name Tagamet among others, is a histamine H2 receptor antagonist that has been a cornerstone in the treatment of various gastrointestinal conditions since its introduction in the late 1970s. Here, we delve into the market dynamics and financial trajectory of cimetidine, exploring its current status, future projections, and the factors influencing its market performance.

Historical Context

Cimetidine was developed in 1971 and came into commercial use in 1977, following approvals in the UK in 1976 and the US in 1979. It was the first drug of its kind to inhibit stomach acid production and was a significant innovation in the treatment of duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD)[5].

Medical Uses and Indications

Cimetidine is indicated for a range of conditions, including duodenal ulcers, gastric ulcers, GERD, and pathological hypersecretory conditions. It is also used to relieve or prevent heartburn and acid indigestion. Its efficacy in reducing stomach acid production has made it a staple in gastrointestinal medicine[5].

Market Players

The global cimetidine market is populated by several key players, including Shanghai Qingping Pharmaceutical Co., Ltd., Guangxi Xiu Xiu Pharmaceutical Co., Ltd., Jiangxi Renqi Pharmaceutical Co., Ltd., Changzhou Kangpu Pharmaceutical Co., Ltd., and international companies like Mylan, AdvaCare Pharma, and Teva Pharmaceuticals USA[1].

Pricing and Cost Analysis

The cost of cimetidine varies based on the dosage and form of the medication. For example, a supply of 10 cimetidine 400 mg oral tablets can cost around $16, depending on the pharmacy. The prices range from $0.78 to $1.63 per unit, depending on the quantity purchased[2].

Oral Liquid and Tablet Prices

  • Oral Liquid: A 237 milliliter supply of cimetidine oral liquid can cost around $519.50, with a per-unit price of $2.19[2].
  • Oral Tablets: Prices for oral tablets range from $14.08 for 30 tablets of 200 mg to $136.40 for 90 tablets of 800 mg[2].

Market Size and Growth Projections

The global cimetidine market is expected to grow significantly over the coming years. Projections indicate that the market will expand from 2022 to 2029, with a notable compound annual growth rate (CAGR). This growth is driven by increasing demand for effective treatments for gastrointestinal disorders and the availability of cimetidine in both prescription and over-the-counter formulations[1][4].

Impact on Healthcare Expenditures

Studies have shown that the introduction of cimetidine has led to significant reductions in healthcare expenditures. For instance, a study using data from the Texas Medicaid program found that total healthcare expenditures for patients with duodenal ulcers were 40% to 63% lower, and days hospitalized were 15% to 33% lower, when treated with cimetidine compared to other treatments[3].

Competitive Landscape

The competitive landscape for cimetidine has evolved with the introduction of proton pump inhibitors (PPIs) like omeprazole, which have similar indications but may offer different efficacy and safety profiles. Despite this, cimetidine remains a viable option due to its long-standing presence in the market and its availability as an over-the-counter medication[5].

Financial Benefits and Cost Savings

The financial benefits of cimetidine are multifaceted. It not only reduces direct healthcare costs by decreasing the need for hospitalizations and other treatments but also provides social benefits through improved health outcomes. A study estimated a reduction of $645 million in healthcare costs for duodenal ulcers at an 80% penetration rate of cimetidine usage[3].

Challenges and Future Outlook

While cimetidine continues to be a valuable treatment option, its market is influenced by several factors, including the availability of alternative treatments like PPIs and the potential for side effects, such as gynecomastia and sexual dysfunction, especially at high doses[5].

Side Effects and Safety Profile

Cimetidine's safety profile includes potential side effects such as gynecomastia, erectile dysfunction, and oligospermia, particularly at higher doses. These side effects can impact its market appeal and usage rates[5].

Regulatory Environment

Cimetidine's regulatory status has evolved over the years. Initially approved as a prescription medication, it is now available in many regions as an over-the-counter drug, which has expanded its market reach and accessibility[5].

Key Takeaways

  • Market Growth: The global cimetidine market is projected to grow significantly from 2022 to 2029.
  • Cost Savings: Cimetidine reduces healthcare expenditures by decreasing hospitalizations and other treatment costs.
  • Competitive Landscape: Despite competition from PPIs, cimetidine remains a viable treatment option.
  • Pricing: The cost of cimetidine varies based on dosage and form, with discounts available through various programs.
  • Regulatory Status: Available as both prescription and over-the-counter medication.

FAQs

What is cimetidine used for?

Cimetidine is used for the treatment of duodenal ulcers, gastric ulcers, gastroesophageal reflux disease (GERD), and pathological hypersecretory conditions. It is also used to relieve or prevent heartburn and acid indigestion[5].

How much does cimetidine cost?

The cost of cimetidine varies based on the dosage and form. For example, a supply of 10 cimetidine 400 mg oral tablets can cost around $16, depending on the pharmacy[2].

What are the potential side effects of cimetidine?

Potential side effects include gynecomastia, erectile dysfunction, oligospermia, and other hormonal changes, particularly at higher doses[5].

How does cimetidine impact healthcare expenditures?

Cimetidine reduces healthcare expenditures by decreasing the need for hospitalizations and other treatments, resulting in significant cost savings[3].

Is cimetidine available over-the-counter?

Yes, cimetidine is available in many regions as an over-the-counter medication, expanding its market reach and accessibility[5].

Sources

  1. Global Cimetidine Tablets Market Research Report 2023 - Valuates Reports
  2. Cimetidine Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com
  3. The Case of a New Drug - Institute for Research on Poverty
  4. Cimetidine Market Size | Share | Scope | Trend & Forecast to 2031 - Market Research Intellect
  5. Cimetidine - Wikipedia

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.